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BACKGROUND: Immunosuppression is a risk factor for certain skin cancers. Autoimmune conditions can involve the skin, and may
involve immunosuppressive therapies.
METHODS: We conducted a population-based case–control study among elderly US adults using Surveillance, Epidemiology, and End
Results-Medicare-linked data of 44613 skin cancer cases and 178452 frequency-matched controls. Medicare claims identified
autoimmune conditions. Adjusted odds ratios (ORs) compared prevalence in cases and controls.
RESULTS: The most frequent autoimmune condition was rheumatoid arthritis (2.29%), which was associated with slightly increased risk
of Merkel cell carcinoma (N¼1977; OR (95%CI): 1.39 (1.10–1.74)). Risk of cutaneous non-Hodgkin’s lymphoma (N¼2652)
was increased with psoriasis (OR (95%CI): 3.20 (2.62–3.92)). Risk of Kaposi’s sarcoma (N¼773) was elevated with ulcerative colitis
(OR (95%CI): 2.76 (1.42–5.39)), and risk of other sarcomas (N¼1324) was elevated with Graves disease (2.62 (1.30–5.31)).
CONCLUSIONS: These findings suggest that immune disturbances in the skin, arising from autoimmune conditions or their treatment,
promote development of skin cancer.
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Established risk factors for skin cancer include exposure to solar
ultraviolet radiation, white race, and advancing age (Gruber and
Armstrong). Immunosuppression also increases the risk of certain
skin cancers. The risk in solid organ transplant recipients and
people with human immunodeficiency virus (HIV) infection is
extremely high for Kaposi’s sarcoma (KS), a cutaneous tumour
caused by human herpesvirus 8, somewhat elevated for cutaneous
non-Hodgkin’s lymphoma (NHL), Merkel cell carcinoma, and
appendageal skin carcinomas and somewhat increased for
melanoma (Lanoy et al, 2010).
Autoimmune conditions may also increase skin cancer risk.
Chronic cutaneous inflammation that can characterise some
autoimmune conditions (including psoriasis and scleroderma,
which directly involve the skin) may plausibly cause DNA damage
that could promote development of skin cancer. Immuno-
suppressive medications used to treat autoimmune conditions
could have an additional role. This study aimed to investigate
associations between autoimmune conditions and the subsequent
risk of skin cancers among elderly US adults (aged 67 years
and over).
MATERIALS AND METHODS
We selected subjects from the Surveillance, Epidemiology, and
End Results (SEER)-Medicare data set, which links SEER cancer
registry and Medicare claims data (Warren et al, 2002). Skin
cancer cases (other than basal and squamous cell carcinomas)
and cancer-free controls were selected as described elsewhere
(Lanoy et al, 2010), updated to include SEER Medicare data
through 2005. The presence of autoimmune conditions before
cancer diagnosis/control selections was assessed using Medicare
claims data: rheumatoid arthritis (International Classification of
Disease version 9 codes 714.0-714.3, 714.81, V82.1), Sjo ¨rgren’s
syndrome (710.2), systemic lupus erythematosus (710.0), poly-
myalgia rheumatica (725), giant cell arteritis (446.5), Addison’s
disease (255.4), Graves disease (242.0), psoriasis (696.0-696.1),
localised scleroderma (701.0), Crohn’s disease (555), ulcerative
colitis (556), and pernicious anaemia (281.0).
We used polytomous logistic regression to derive odds ratios
(ORs) comparing the prevalence of each medical condition in skin
cancer cases to controls (Lanoy et al, 2010). We focused on
associations that met statistical significance after Benjamini and
Hochberg correction to account for multiple comparisons (P-value
o0.05, after correction based on 6 skin cancers subtypes 12
autoimmune conditions¼72 tests) (Keselman et al, 2002), but we
also present uncorrected 95%CIs for ORs that indicate associations
of borderline significance (uncorrected P-value o0.05).
RESULTS
Characteristics of 44613 skin cancer cases and 178452 controls
(corresponding to 134779 unique control individuals) are
shown in Table 1. Among 1540 appendageal carcinoma cases, the
most frequent histological subtypes were sebaceous carcinoma
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y(N¼610), skin appendage carcinoma (N¼316), and sweat
gland adenocarcinoma (N¼144). Of the 2652 cutaneous NHLs,
1854 were T-cell NHLs (of which 945 were mycosis fungoides/
Sezary syndrome (MF/SS)) and 798 were B-cell NHLs. Among
1324 sarcomas, the most frequent histological subtypes were
malignant fibrous histiocytoma (N¼682), dermatofibrosarcoma
(N¼235), haemangiosarcoma (N¼173), and leiomyosarcoma
(N¼121).
As shown in Table 2, an increased risk of Merkel cell carcinoma
was observed in persons with rheumatoid arthritis (OR 1.39).
Psoriasis was associated with an increased risk of cutaneous
NHL (OR 3.20), caused by associations specifically with MF/SS
(OR 5.81, 95% CI 4.43–7.63) and other cutaneous T-cell NHLs
(OR 2.90, 95% CI 2.07–4.06), whereas cutaneous B-cell NHL risk
was not elevated (OR 1.04, 95% CI 0.57–1.89). Ulcerative colitis
was associated with risk of KS (OR 2.76), and an increased risk
of sarcoma was found with Graves disease (OR 2.62). Among
sarcomas, when we considered only malignant fibrous histio-
cytoma, the association with Graves disease remained significant
(OR 3.24, 95% CI 1.33–7.89). Finally, melanoma risk was decreased
in individuals with giant cell arteritis (OR 0.70). Table 2 also shows
several additional associations of borderline significance.
DISCUSSION
We evaluated the risk of non-keratinocytic skin cancers in patients
with autoimmune conditions in a case–control study among
elderly US adults. Some associations that met our criterion for
significance are likely to be explained by chronic inflammatory
involvement of the skin or immune modulating therapies given for
autoimmune conditions. The strong association that we observed
between psoriasis and T-cell NHL (particularly MF/SS) is a
biologically plausible manifestation of chronic inflammation
(Ekstrom Smedby et al, 2008; Anderson et al, 2009). An alternative
explanation could be misdiagnosis, in that cutaneous lymphoma
can initially present as a chronic plaque-like lesion that might be
mistaken for psoriasis (Ekstrom Smedby et al, 2008). In contrast,
psoriasis was neither associated with cutaneous B-cell NHL nor,
in a prior study (Anderson et al, 2009), with non-cutaneous
T-cell NHL.
Our finding of elevated KS risk associated with ulcerative colitis
is supported by several case reports in such patients receiving
immunosuppressive drugs (Svrcek et al, 2009). The association of
sarcoma with Graves disease mentioned above may relate to
immunosuppressive therapies (Simon et al, 2009), as may that of
rheumatoid arthritis with Merkel cell carcinoma, which is
increased in HIV-infected people and transplant recipients (Lanoy
et al, 2010) and may be caused by a recently discovered
polyomavirus. Finally, we observed an unexpected significant
deficit of melanoma among people with giant cell arteritis. A
Danish study found no association between autoimmune diseases
and melanoma incidence (Kaae et al, 2007), although others have
reported an increased melanoma risk with pernicious anaemia
(Brinton et al, 1989) and psoriasis (Stern, 2001).
The strength of our study is its large size, allowing us to evaluate
associations between uncommon autoimmune conditions and skin
cancers. Nonetheless, limitations of our study include that it was
restricted to elderly adults, that basal and squamous cell skin
cancers were not covered, and that we could not ascertain the
presence of medical conditions below 65 years of age; we also had
no data on immunosuppressive treatments.
Several associations identified between autoimmune conditions
and skin cancer risk suggest that such conditions affecting the
skin, or treated with immunosuppression promote the develop-
ment of skin cancer; their further investigation will require
additional large studies.
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Table 1 Characteristics of skin cancer cases and controls among elderly US adults
Skin cancer cases
Controls Melanoma
Merkel cell
carcinoma
Appendageal
carcinomas
Cutaneous
NHL KS Sarcomas
N¼178452 N¼36092 N¼1977 N¼1540 N¼2652 N¼773 N¼1324
Gender, n (%)
Male 109316 (61.3) 22293 (61.8) 1186 (60.0) 785 (51.0) 1478 (55.7) 514 (66.5) 935 (70.6)
Female 69136 (38.7) 13799 (38.2) 791 (40.0) 755 (49.0) 1174 (44.3) 259 (33.5) 389 (29.4)
Age in years, n (%)
67–69 28884 (16.2%) 6142 (17.0%) 182 (9.2%) 186 (12.1%) 443 (16.7%) 82 (10.6%) 158 (11.9%)
70–74 42792 (24.0%) 8957 (24.9%) 330 (16.7%) 311 (20.2%) 645 (24.3%) 136 (17.6%) 267 (20.2%)
75–79 43392 (24.3%) 8870 (24.6%) 439 (22.2%) 361 (23.4%) 661 (24.9%) 147 (19.0%) 309 (23.3%)
80–84 34928 (19.6%) 6838 (18.9%) 512 (25.9%) 317 (20.6%) 516 (19.5%) 171 (22.1%) 320 (24.2%)
85+ 28456 (15.9%) 5285 (14.6%) 514 (26.0%) 365 (23.7%) 387 (14.6%) 237 (30.7%) 270 (20.4%)
Median age (years) 76 76 80 78 76 80 79
Calendar year of diagnosis/
selection, median (IQR)
2001 (1996–2003) 2001 (1996–2003) 2001 (1997–2003) 2000 (1993–2003) 2000 (1995–2003) 1998 (1993–2002) 2000 (1995–2003)
Duration of Medicare
coverage, months,
median (IQR)
95 (50–150) 93 (49–146) 118 (71–171) 106 (59–161) 93 (50–143) 90 (47–146) 103 (58–156)
Number of physician claims
a,
median (IQR)
37 (6–96) 38 (7–91) 65 (17–138) 51 (9.5–110.5) 40 (7–95) 33 (1–94) 43 (8–102)
Number of hospital claims
a,
median (IQR)
0(0–2) 0(0–2) 1(0–3) 1(0–2) 0(0–2) 1(0–2) 1(0–2)
Number of outpatient claims
a,
median (IQR)
4 (0–14) 4 (0–13) 6 (1–20) 5 (0–16) 4 (0–14) 2 (0–10) 4 (0–15)
Abbreviations: IQR¼interquartile range; KS¼Kaposi’s sarcoma; NHL¼non-Hodgkin’s lymphoma.
aThe number of claims excludes the 12 months before skin cancer diagnosis
(cases) or selection (controls).
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Table 2 Associations of autoimmune conditions with skin cancer risk among elderly US adults
Associations with autoimmune condition: OR (95%CI) and number of subjects
with the specified condition
Controls with
condition (%) Melanoma
Merkel cell
carcinoma
Appendageal
carcinomas
Cutaneous
NHL KS Sarcomas
N¼178452 N¼36092 N¼1977 N¼1540 N¼2652 N¼773 N¼1324
Systemic/connective tissue
Rheumatoid
arthritis
2.29 0.93 (0.86–1.01)
n¼758
1.39 (1.10–1.75)
a
n¼79
1.02 (0.74–1.39)
n¼42
1.15 (0.90–1.46)
n¼72
1.65 (1.09–2.49)
n¼25
1.13 (0.79–1.60)
n¼33
Sjo ¨rgren’s
syndrome
0.21 1.00 (0.77–1.30)
n¼73
1.46 (0.72–2.96)
no11
1.76 (0.83–3.74)
no11
1.02 (0.45–2.30)
no11
0.73 (0.10–5.22)
no11
1.97 (0.81–4.82)
no11
Systemic lupus
erythematosus
0.20 0.80 (0.60–1.06)
n¼57
1.02 (0.42–2.47)
no11
1.62 (0.71–3.66)
no11
1.73 (0.91–3.27)
no11
1.65 (0.41–6.65)
no11
0.85 (0.21–3.45)
no11
Polymyalgia
rheumatica
0.97 1.04 (0.92–1.17)
n¼353
1.03 (0.71–1.51)
n¼28
0.90 (0.55–1.46)
n¼17
0.71 (0.45–1.12)
n¼19
1.73 (0.99–3.01)
n¼13
0.74 (0.40–1.40)
no11
Cardiovascular
Giant cell arteritis 0.30 0.70 (0.54–0.90)
a
n¼72
1.41 (0.79–2.50)
n¼12
0.83 (0.34–2.02)
no11
0.85 (0.40–1.80)
no11
0.87 (0.22–3.50)
no11
1.50 (0.67–3.38)
no11
Endocrine
Addison’s disease 0.13 1.06 (0.77–1.45)
n¼49
0.56 (0.14–2.27)
no11
1.28 (0.41–4.02)
no11
1.13 (0.42–3.05)
no11
1.98 (0.48–8.15)
no11
0.53 (0.07–3.83)
no11
Graves disease 0.24 0.88 (0.68–1.13)
n¼75
1.43 (0.73–2.78)
no11
0.67 (0.21–2.09)
no11
1.20 (0.59–2.43)
no11
0 2.62 (1.30–5.31)
a
no11
Skin
Psoriasis 1.33 0.87 (0.78–0.97)
n¼418
1.29 (0.94–1.76)
n¼42
1.36 (0.94–1.97)
n¼30
3.20 (2.62–3.92)
a
n¼108
1.20 (0.66–2.21)
n¼11
0.99 (0.61–1.58)
n¼18
Localised
scleroderma
0.14 0.85 (0.60–1.19)
n¼41
1.39 (0.57–3.40)
no11
1.11 (0.35–3.47)
no11
2.06 (1.01–4.19)
no11
2.34 (0.58–9.45)
no11
1.27 (0.31–5.15)
no11
Gastrointestinal
Crohn’s disease 0.27 1.12 (0.90–1.39)
no116
0.46 (0.15–1.45)
no11
2.25 (1.20–4.23)
no11
1.26 (0.65–2.46)
no11
1.09 (0.27–4.44)
no11
0.56 (0.14–2.26)
no11
Ulcerative colitis 0.48 1.08 (0.91–1.27)
n¼183
0.83 (0.44–1.56)
no11
0.98 (0.49–1.98)
no11
1.34 (0.82–2.17)
n¼17
2.76 (1.42–5.39)
a
no11
1.24 (0.61–2.49)
no11
Pernicious anaemia 1.57 0.90 (0.81–0.99)
n¼491
0.87 (0.63–1.20)
n¼39
0.84 (0.56–1.25)
n¼25
1.05 (0.78–1.43)
n¼44
0.77 (0.41–1.44)
no11
1.15 (0.78–1.71)
n¼26
Abbreviations: OR¼odds ratio; CI¼confidence interval; KS¼Kaposi’s sarcoma; NHL¼non-Hodgkin’s lymphoma. Odds ratios are adjusted for age (67–69, 70–74, 75–79,
80–84, and 85–99 years), gender, selection year (1987–1993, 1994–1997, 1998–2000, and 2000–2002), and number of physician claims (0–4, 5–39, 40–109, and 110+).
For consistency, all odds ratios are displayed to two decimal places, although in some instances the number of subjects with the specified medical condition is small. When the
number of subjects with the autoimmune condition was between 1 and 10, the result is listed as ‘no11’ to preserve subjects’ anonymity in accordance with the SEER-Medicare
data use agreement.
aAssociation was significant after accounting for multiple testing using the Benjamini and Hochberg correction.
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